Abstract
The first basket clinical trial testing the BRAF inhibitor vemurafenib resulted in evidence of activity in 13 unique cancer types with BRAFV600 mutations, but the response rates were variable. Therefore, different cancer histologies with the same driver oncogene display different degrees of oncogenic pathway addiction.
Cite
CITATION STYLE
APA
Ribas, A., & Lo, R. S. (2020, May 1). Trying for a braf slam dunk. Cancer Discovery. American Association for Cancer Research Inc. https://doi.org/10.1158/2159-8290.CD-20-0231
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free